Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Dawes-Redman Education programme which offers virtual CTG Analysis training sessions to Obstetric consultants, antenatal and student midwifes has received generous funds from Huntleigh Healthcare for the next 3 years.

In 1980, University of Oxford Professors Geoffrey Dawes and Chris Redman initiated a pioneering programme to computerise the recognition of diagnostic features of electronic fetal heart rate traces before labour. The Dawes-Redman CTG Analysis System represents one of the University’s most successful and long-standing clinical  advances, and is widely recognised as the reference standard for the assessment of fetal health during pregnancy.

The system has undergone extensive testing and continual refinement over the last 40 years and supported by over 70 peer-reviewed articles, has a proven level of performance accepted by clinicians worldwide.

The Dawes-Redman antepartum CTG  is recommended by NHS England as the best way to assess the fetus before labour. It analyses the fetal heart and measures a number of criteria. These provide a readout of the hypoxic status of the baby since the fetal heart is controlled by the fetal brain. 

The requirement for training in the use of CTG has been highlighted by a number of clinical bodies including the Saving Babies Lives Care Bundle 2, the Healthcare Safety  Investigation Branch and the Ockendon Report. 

The team at Oxford comprising Professor Redman (co-inventor of the Dawes-Redman system), Beth Albert (Director of Dawes-Redman Education) and Manu Vatish (Professor of Obstetrics) have created a bespoke education programme for Dawes-Redman to address these needs  This has only been possible by the generous support of Huntleigh Healthcare who have pledged £131,600 over three years. 

Prof Many Vatish commented: "The Nuffield Department of Women's & Reproductive Health, University of Oxford are extremely grateful for Huntleigh Healthcare's generous donation in support of the educational training programme for Dawes-Redman CTG Analysis."

The virtual training sessions are led by Beth Albert, who is a Lead Midwife/ Manager in the Fetal Maternal Medicine Unit at Oxford University Hospital Foundation Trust. She is a specialist midwife for Dawes-Redman CTG monitoring and the lead for education.



Similar stories

First UK pilot study of newborn screening for spinal muscular atrophy (SMA) launched in Oxford

Spinal muscular atrophy (SMA) is a rare, but treatable, genetic disease affecting approximately 1 in 10,000 births, and it typically presents in infancy and early childhood.

Professor Collins awarded Sir Jules Thorn Translational Biomedical Research Award 2021

Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.

Global INTERCOVID-2022 Study launched to compare Covid-19 during pregnancy, with pregnant women without the infection.

The Oxford Maternal & Perinatal Health Institute (OMPHI) has launched the 2022 round of the global study to evaluate the effects of Covid-19 variants and vaccination in pregnancy.

Success with the Pfizer Maternal C-19 Vaccine Trial

Congratulations to Prof. Manu Vatish and the OSPREA-Gynae team on recruiting their first participant to the Pfizer maternal C-19 vaccine trial on 22nd July.

How do unborn babies and mothers communicate via the placenta?

DPhil student Neva Kandzija wins an Oxford Sparks competition to have her Placenta research transformed into a two minute animation film for free.

100 000 babies screened for increased type 1 diabetes risk in the INGR1D Study

Celebrating a major milestone for one of Europe’s biggest type 1 diabetes research cooperations: The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has successfully screened 100,000 newborns across Europe (including over 7500 newborns in the Thames Valley) for an increased genetic risk of developing type 1 diabetes.